Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Jul;38(1):77–79. doi: 10.1111/j.1365-2125.1994.tb04325.x

The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients.

R A Yeates 1, M Ruhnke 1, G Pfaff 1, A Hartmann 1, M Trautmann 1, E Sarnow 1
PMCID: PMC1364841  PMID: 7946940

Abstract

The pharmacokinetics of fluconazole after a single 100 mg i.v. dose were studied in 10 healthy subjects (5 M; 5 F) and 10 HIV-positive patients (8 M; 2 F). The mean value of plasma clearance was 25% lower in the patient groups (17 +/- 6 (s.d.) vs 23 +/- 4 ml min-1; 95% CI of difference -11 to -0.7; P < 0.05). This difference may have been related to slightly reduced kidney function in the patient group (mean creatinine clearance -18%) but is unlikely to be clinically significant. Therefore, no adjustment of the dose of intravenously administered fluconazole appears to be necessary in AIDS patients without clinical signs of enteropathy.

Full text

PDF
77

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brammer K. W., Farrow P. R., Faulkner J. K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S318–S326. doi: 10.1093/clinids/12.supplement_3.s318. [DOI] [PubMed] [Google Scholar]
  2. Coleburn N. H., Scholes J. V., Lowe F. C. Renal failure in patients with AIDS-related complex. Urology. 1991 Jun;37(6):523–527. doi: 10.1016/0090-4295(91)80316-y. [DOI] [PubMed] [Google Scholar]
  3. Dupont B., Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol. 1988 Feb;26(1):67–71. doi: 10.1080/02681218880000081. [DOI] [PubMed] [Google Scholar]
  4. Foulds G., Brennan D. R., Wajszczuk C., Catanzaro A., Garg D. C., Knopf W., Rinaldi M., Weidler D. J. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol. 1988 Apr;28(4):363–366. doi: 10.1002/j.1552-4604.1988.tb03159.x. [DOI] [PubMed] [Google Scholar]
  5. Larsen R. A. Azoles and AIDS. J Infect Dis. 1990 Sep;162(3):727–730. doi: 10.1093/infdis/162.3.727. [DOI] [PubMed] [Google Scholar]
  6. Lazar J. D., Wilner K. D. Drug interactions with fluconazole. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S327–S333. doi: 10.1093/clinids/12.supplement_3.s327. [DOI] [PubMed] [Google Scholar]
  7. Powderly W. G., Saag M. S., Cloud G. A., Robinson P., Meyer R. D., Jacobson J. M., Graybill J. R., Sugar A. M., McAuliffe V. J., Follansbee S. E. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. 1992 Mar 19;326(12):793–798. doi: 10.1056/NEJM199203193261203. [DOI] [PubMed] [Google Scholar]
  8. Saag M. S., Powderly W. G., Cloud G. A., Robinson P., Grieco M. H., Sharkey P. K., Thompson S. E., Sugar A. M., Tuazon C. U., Fisher J. F. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992 Jan 9;326(2):83–89. doi: 10.1056/NEJM199201093260202. [DOI] [PubMed] [Google Scholar]
  9. Vincent-Ballereau F. N., Patey O. N., Lafaix C. Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections. Pharm Weekbl Sci. 1991 Apr 26;13(2):45–57. doi: 10.1007/BF01974981. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES